Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.
The vaccine is based on Intravacc’s Outer Membrane Vesicles (OMV) platform. Under the collaboration agreement, Intravacc’s immunogenic OMV delivery platform will unite with EpiVax’s synthetically generated Covid-19 epitopes designed and optimised using immunoinformatics tools.
The aim is to produce a safe and effective T-cell response against SARS-CoV-2 and other related coronaviruses. Our parent business intelligence company EpiVax CEO and CSO Annie De Groot said: “We are thrilled to enter into a partnership with Intravacc using their very novel ‘click-on’ OMV technology and the